Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL7-H52H7 | Human | Human IL-7 R alpha / CD127 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL7-H82F9 | Human | Biotinylated Human IL-7 R alpha / CD127 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
ILR-M5253 | Mouse | Mouse IL-7 R alpha / CD127 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILA-H525a | Human | Human IL-7 R alpha / CD127 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL7-H5258 | Human | Human IL-7 R alpha / CD127 Protein (I66T, V138I), Mouse IgG2a Fc Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Captured Human IL-7 R alpha, Mouse IgG2a Fc Tag (Cat. No. IL7-H5258) on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) with an affinity constant of 13.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Interleukin-7 (Revimmune SAS) | rhIL-7; CYT-107; CYT-99-007 | Phase 2 Clinical | Revimmune Inc | Prostatic Neoplasms, Castration-Resistant; Neuroectodermal Tumors, Primitive, Peripheral; Catheter-Related Infections; Rhabdomyosarcoma, Alveolar; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Metastatic breast cancer; Hepatitis C; Ureteral Neoplasms; Urologic Neoplasms; Lymphopenia; Sarcoma; Neuroblastoma; Prostatic Neoplasms; Urethral Neoplasms; Multiple Myeloma; HIV Infections; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Sepsis; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Mycobacterium Infections, Nontuberculous; Myelodysplastic Syndromes; Rhabdomyosarcoma, Embryonal; Hepatitis B, Chronic; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic; Kidney Neoplasms; Skin Melanoma; Shock, Septic | Details |
Lusvertikimab | S-95011; Effi-7; OSE-217; OSE-127 | Phase 2 Clinical | Effimune | Sjogren's Syndrome; Colitis, Ulcerative | Details |
Efineptakin alfa | TJ-107; GX-I7; NT-I7 | Phase 2 Clinical | Genexine Inc | Urinary Bladder Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Non-Small-Cell Lung; Laryngeal Neoplasms; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gliosarcoma; Lymphopenia; Astrocytoma; Colorectal Neoplasms; Plasmablastic Lymphoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Hypopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Carcinoma, Merkel Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Ovarian Neoplasms; Lymphoma, B-Cell | Details |
ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Solid tumours | Details |
This web search service is supported by Google Inc.